An FDA advisory panel reviews seven popular peptides like TB-500 and BPC-157 for compounding pharmacy access, despite lacking large-scale human trials. Proponents cite benefits for recovery and metabolism, while scientists warn of limited data and safety risks.
FDA panel weighs lifting peptide therapy restrictions
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →